---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010956"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:26:41.979169+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IN8bio reports FY2022 net loss $28.5M; cash $18.2M; clinical data positive

## Summary
- Cash $18.2M at Dec 31, 2022, down from $37.0M a year earlier; R&D spend $14.1M (FY2022) vs $7.3M.
- Net loss $28.5M ($1.36/share) for FY2022 vs $14.7M ($1.47/share) in FY2021; Q4 loss $7.8M ($0.32/share).
- INB-100 leukemia patients maintain durable complete responses beyond 18 months, up to 2.7 years in Phase 1.
- INB-200 GBM trial: two patients progression-free at 1.5 and 1.2 years; enrolling Cohort 3; updated data mid-2023.
- FDA cleared IND for INB-400 Phase 2 trial in GBM; enrollment expected H2 2023.

## SEC filing metadata
- accession: 0000950170-23-010956
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000095017023010956/0000950170-23-010956-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000095017023010956/inab-20230330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010956
- JSON: https://secwatch.observer/filing/0000950170-23-010956.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010956.txt

## Key facts
- Earnings Releases
  IN8BIO, INC. reported financial results for the fourth quarter and full-year ended December 31, 2022.
  - Period: the fourth quarter and full-year ended December 31, 2022
  - Result: reported results
  source text: On March 30, 2023, IN8bio, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1740279/000095017023010956/0000950170-23-010956-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.